Emicizumab, a bispecific antibody that bridges clotting factors IX and X, restores factor VIII function and prevents bleeding in hemophilia A with infrequent injections.

A study finds that mammalian cells can join RNA from separate genes into functional hybrid proteins, revealing a hidden layer of genome complexity in immune cells.

The inherited mutation substantially increases the chance of developing lung cancer, including in people who don’t smoke.

A one-time infusion of sugar-tagged bone marrow cells cut fragility fractures 94% in an osteoporosis trial, pointing toward a potential bone-regeneration treatment.

GLP-1 prescriptions are soaring for younger children despite the medications not being approved for this age group. Are they safe and effective in these children?

NHS hasn’t budgeted for the spending increase entailed by the U.S.-U.K. deal to allow payment for more drugs while keeping funding levels constant for other healthcare.

The Trump administration has made bold claims about how much GLOBE and GUARD models will save Medicare. But most of those vanish once the exemptions are accounted for.

By remaining shrouded in mystery, the MFN deals agreed to with drug makers reveal too little to tell how much money they’ll save governments as well as taxpayers and patients.

A new two-step method makes more uniform antibody-drug conjugates by attaching cancer drugs at a precise antibody site, simplifying targeted cancer drug development.

FDA-approved daraxonrasib targets RAS in metastatic pancreatic cancer, doubling median survival versus chemotherapy and delivering a long-awaited treatment advance.